AI assistant
Sending…
GALECTIN THERAPEUTICS INC — Director's Dealing 2026
Jan 21, 2026
33422_dirs_2026-01-21_2cd947e2-1e14-4b24-b4a7-ae3f52eaf691.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2026-01-16
Reporting Person: Schwartz Elissa J. (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2026-01-16 | Stock option (right to buy) | $3.04 | A | 60000 | Acquired | 2036-01-16 | Common Stock (60000) | Direct |
Footnotes
F1: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.
F2: The options vest 100% on December 31, 2026.
More from GALECTIN THERAPEUTICS INC
Regulatory Filings
2026
May 15
Interim / Quarterly Report
2026
May 15
Regulatory Filings
2026
Mar 31
Regulatory Filings
2026
Mar 31
Annual Report
2026
Mar 31
Director's Dealing
2026
Mar 17
Director's Dealing
2026
Mar 17
Regulatory Filings
2026
Mar 17
Director's Dealing
2026
Feb 9
Regulatory Filings
2026
Jan 21